August 4, 2014Human Psychopharmacology Clinical and ExperimentalOpen Access

A randomised, double‐blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine

View Full Paper

Ask AI

Bookmark

Abstract

Vortioxetine was noninferior and significantly superior to agomelatine in major depressive disorder patients with previous inadequate response to a single course of SSRI/SNRI monotherapy. Vortioxetine was safe and well tolerated.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Montgomery et al. (2014) studied this question.

synapsesocial.com/papers/69dcc9aaf3d3790cb7133dad https://doi.org/10.1002/hup.2424

View Full Paper

Ask AI

Bookmark

A randomised, double‐blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine

Abstract

Discussion

Cite This Study

A randomised, double‐blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine

Abstract

Discussion

Cite This Study

Keep reading

Keep reading